K. Rex

发表

Abstract 55: Generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing

T. Arvedson, M. Balázs, P. Bogner, 2017 .

Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).

K. Rex, Matthew R. Lee, C. Dominguez, 2008, Journal of Medicinal Chemistry.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

K. Rex, K. Shah, Douglas Hoffman, 2008, Journal of medicinal chemistry.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice.

D. Lacey, K. Rex, S. Scully, 1999, International journal of radiation biology.

Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity

P. Span, A. Heerschap, P. Wesseling, 2017, Molecular Cancer Research.

Discovery of AMG 458: A Potent, Selective, and Orally Bioavailable c-Met Inhibitor

K. Rex, Matthew R. Lee, S. Bellon, 2008 .

rHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease.

D. Lacey, D. Danilenko, K. Rex, 2002, American journal of physiology. Gastrointestinal and liver physiology.

The effects of keratinocyte growth factor in preclinical models of mucositis

D. Lacey, K. Rex, S. Scully, 2002, Cell proliferation.

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade

R. Heist, W. Haas, R. Morris, 2022, bioRxiv.

A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis.

K. Rex, P. Wei, S. Scully, 2006, International journal of radiation oncology, biology, physics.

Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met–dependent tumors in animal models

K. Rex, A. Coxon, R. Radinsky, 2009, Molecular Cancer Therapeutics.

Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors.

N. Chen, J. McCarter, K. Rex, 2019, Journal of medicinal chemistry.

Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.

K. Rex, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

Yuan Cheng, K. Rex, A. Coxon, 2008, Journal of medicinal chemistry.

c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations*

K. Rex, A. Coxon, A. Tasker, 2008, Journal of Biological Chemistry.

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.

Jilin Sun, Qing Chen, Ke Zhang, 2006, Cancer research.

Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.

D. Lacey, K. Rex, C. Potten, 1998, Cancer research.

Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma

K. Rex, A. Coxon, S. Ramakrishnan, 2019, Molecular Cancer Therapeutics.

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

J. Desai, R. Govindan, W. Ouyang, 2019, Nature.

AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

K. Rex, A. Coxon, R. Radinsky, 2007, Clinical Cancer Research.

Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.

K. Rex, A. Coxon, B. Bolon, 2002, Arthritis and rheumatism.

Sphingosine Kinase Activity Is Not Required for Tumor Cell Viability

K. Rex, A. Coxon, N. Walker, 2013, PloS one.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

K. Rex, A. Coxon, M. Damore, 2016, Molecular Cancer Therapeutics.

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

Liaoyuan A. Hu, O. Wang, K. Rex, 2015, Molecular Cancer Therapeutics.

The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine.

K. Rex, C. Potten, C. Booth, 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Influences of neurotrophins on mammalian motoneurons in vivo.

K. Rex, W. Snider, J. Sun, 1993, Journal of neurobiology.

Small-molecule Kinase Inhibitor with Antitumor Activity Identification of a Novel Recepteur D'origine Nantais/c-met Material Supplementary Cited Articles Citing Articles E-mail Alerts Identification of a Novel Recepteur D'origine Nantais/c-met Small-molecule Kinase Inhibitor with Antitumor Activity

K. Rex, A. Coxon, T. Burgess, 2022 .

Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling

C. Vocke, K. Rex, A. Coxon, 2023, Cancers.

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

Paul Hughes, Richard Kendall, T. Bush, 2009, Clinical Cancer Research.

BroadAntitumorActivity inBreastCancerXenograftsbyMotesanib , aHighly Selective , Oral Inhibitorof Vascular Endothelial Growth Factor , Platelet-DerivedGrowth Factor , andKit Receptors

T. Bush, K. Rex, A. Coxon, 2008 .

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

K. Furge, G. V. Vande Woude, K. Rex, 2009, Molecular Cancer Therapeutics.

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

L. Nguyen, D. McDonald, K. Rex, 2010, Molecular Cancer Therapeutics.

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.

K. Rex, A. Coxon, T. Burgess, 2008, Cancer research.

Structure guided design of a series of sphingosine kinase (SphK) inhibitors.

Holger Wesche, Frank Kayser, Alan C Cheng, 2013, Bioorganic & medicinal chemistry letters.

Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.

K. Rex, J. Canon, B. Herberich, 2019, Journal of medicinal chemistry.

Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.

K. Rex, B. Herberich, Matthew R. Lee, 2016, Journal of medicinal chemistry.

Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors.

K. Rex, B. Herberich, Matthew R. Lee, 2016, ACS medicinal chemistry letters.

Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

K. Rex, A. Coxon, R. Radinsky, 2014 .

text-Dependent Role of Angiopoietin-1 Inhibition in the pression of Angiogenesis and Tumor Growth: Implications

L. Nguyen, K. Rex, T. Boone, 2010 .

apeutic Discovery text-Dependent Role of Angiopoietin-1 Inhibition in the pression of Angiogenesis and Tumor Growth : Implications Ther AMG 386 , an Angiopoietin-1 / 2 – Neutralizing Peptibody

L. Nguyen, D. McDonald, K. Rex, 2010 .

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

K. Rex, A. Coxon, D. Whittington, 2016, Journal of medicinal chemistry.

Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2015, Journal of medicinal chemistry.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2012, Bioorganic & Medicinal Chemistry Letters.

Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.

S. Gambhir, K. Rex, A. Coxon, 2013, Nuclear medicine and biology.

Recombinant human keratinocyte growth factor (rHuKGF) ameliorates disease symptoms in both the DSS and CD45RB hi cell transfer murine models of inflammatory bowel disease (IBD)

D. Lacey, D. Danilenko, K. Rex, 2001 .

Keratinocyte Growth Factor Protects Mice from Chemotherapy and Radiation-induced Gastrointestinal Injury and Mortality 1

D. Lacey, K. Rex, C. Potten, 1998 .

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Abstract 4484: Discovery and in vitro characterization of AMG 510–a potent and selective covalent small-molecule inhibitor of KRASG12C

J. McCarter, K. Rex, J. Canon, 2019, Experimental and Molecular Therapeutics.

LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

R. Heist, K. Rex, J. Lipford, 2024, bioRxiv.

Keratinocyte Growth Factor Protects Mice from Chemotherapy and Radiation-induced Gastrointestinal Injury and Mortality1

Catherine, D. Lacey, K. Rex, 2006 .